Soleno Therapeutics (SLNO) Intangibles (2015 - 2026)

Soleno Therapeutics (SLNO) has 12 years of Intangibles data on file, last reported at $4.4 million in Q1 2026.

• On a quarterly basis, Intangibles fell 30.77% year-over-year to $4.4 million in Q1 2026; TTM through Mar 2026 was $4.4 million, a 30.77% decrease from a year earlier, with the FY2025 full-year figure at $4.9 million, down 28.57% from the prior year.
• Intangibles for Q1 2026 stood at $4.4 million, down from $4.9 million in the prior quarter.
• Over the last five years, Intangibles for SLNO reached as high as $12.2 million in Q1 2022 and fell as low as $4.4 million in Q1 2026.
• Historically, Intangibles has averaged $8.3 million across 5 years, with a median of $8.3 million in 2024.
• Across the five-year window, Intangibles dropped 13.79% in 2022 and tumbled 30.77% in 2026, its largest moves.
• Year by year, Intangibles stood at $10.7 million in 2022, then fell by 18.18% to $8.7 million in 2023, then retreated by 22.22% to $6.8 million in 2024, then decreased by 28.57% to $4.9 million in 2025, then slipped by 10.02% to $4.4 million in 2026.
• Per Business Quant data, the three most recent Intangibles figures were $4.4 million in Q1 2026, $4.9 million in Q4 2025, and $5.3 million in Q3 2025.